Biocartis to showcase Idylla™ at USCAP 2025 in Boston

Biocartis NV announced that it will present several research findings on its Idylla™ Platform at the upcoming United States and Canadian Academy of Pathology (USCAP) 2025 Annual Meeting in Boston, from March 22 to 27. These findings come from recognized institutions and emphasize the platform's capabilities in oncology diagnostics. Multiple abstracts will showcase the Idylla™ System's rapid and fully automated testing for various cancer types like lung, thyroid, endometrial, and colorectal cancers. Research highlights include a study from MD Anderson Cancer Center that shows high accuracy in detecting KRAS and EGFR mutations using cytology samples from lung cancer patients. Another study from Memorial Sloan Kettering Cancer Center evaluates the Idylla™ BRAF Mutation Assay for thyroid cancer, emphasizing its speed and reliability compared to traditional methods. Additional presentations will focus on endometrial carcinoma and comparisons between the Idylla™ System and other testing systems for non-small cell lung cancer. Biocartis aims to demonstrate how Idylla™ can improve molecular testing in real-world laboratories. These studies highlight the system's effectiveness in providing quick and actionable results, which can enhance patient management. Biocartis encourages attendees to visit their booth to learn more about the innovative features of the Idylla™ Platform.